Search clinical trials for: JNJ-64304500

Total 1086 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity
Janssen Research & Development, LLC

Terminated

Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer

Advanced Prostate Cancer

France, United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers

Healthy
Janssen R&D Ireland

Terminated

A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients

Chronic Hepatitis C Infection

Taiwan
Janssen Research & Development, LLC

Withdrawn

A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate

Active Rheumatoid Arthritis; Rheumatoid Arthritis
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis (ANTHEM-UC)

Colitis, Ulcerative

Korea, Republic of, Australia, United States, Czechia, Malaysia, Turkey, Japan, Belgium, Hungary, Canada, Italy, Spain, China, Poland, United Kingdom, Germany, Brazil, France, Argentina, Romania, India
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-64281802 for the Prevention of Dengue Infection

Dengue

Mexico, Malaysia, Brazil, Colombia, Puerto Rico, Panama, Peru, Philippines, Thailand
Janssen Research & Development, LLC

Recruiting

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
University of Oxford
Janssen Pharmaceutica

Terminated

MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease (MICAD)

Alzheimer Disease | Mild Cognitive Impairment

United Kingdom
Janssen Research & Development, LLC

No longer available

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Belgium, Iceland, Portugal, Slovenia
Janssen Research & Development, LLC

Completed

Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity

Insomnia

Germany, United States, Netherlands
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Brazil, Germany, Italy, Netherlands, Romania, Switzerland, United Kingdom
Janssen Research & Development, LLC

Completed

A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

Fatty Liver Disease

United States
Janssen Research & Development, LLC

Terminated

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

Germany
Janssen Research & Development, LLC

Completed

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Spain, United States, Hungary, Georgia, Moldova, Republic of, Ukraine
Janssen Research & Development, LLC

Completed

A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli

United States, Germany, Korea, Republic of, France, Netherlands, Spain, Puerto Rico
Janssen Research & Development, LLC

Completed

A Study of JNJ-42847922 (Seltorexant) in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Approved for marketing

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Relapsed or Refractory Multiple Myeloma
Janssen-Cilag International NV

Terminated

A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment

Kidney Failure, Chronic

Germany
Janssen Research & Development, LLC

Terminated

A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis

Healthy | Colitis, Ulcerative

Germany
Janssen Research & Development, LLC

Completed

A Study of Seltorexant in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

Hepatic Impairment

Germany
Tangent Data
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive (JNJ-DEP)

Depression

Moldova, Republic of, Romania
Janssen-Cilag International NV

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274

Healthy

United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Participants

Healthy

Netherlands
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

Attention Deficit Hyperactivity Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39393406 in Healthy Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Exploratory Study to Assess the Effects of JNJ-39439335 on the Relief of Pain Using a Thermal-Grill Experimental Model

Pain
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)

Bladder Cancer

United States, Belgium, Korea, Republic of, Italy, Taiwan, China, United Kingdom, Germany, France, Argentina, Brazil, Poland, Spain, Czechia, Japan, Netherlands, India, Canada, Mexico, Australia, Portugal
Janssen Research & Development, LLC

Completed

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

Depressive Disorder, Major

Belgium, United Kingdom, Germany, United States, Netherlands
Janssen Research & Development, LLC

Completed

A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Belgium, Israel, Spain
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery (TEXT-TKR)

VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

Belgium, Italy, Malaysia, Latvia, Spain, Turkey, Bulgaria, United States, Lithuania, Russian Federation, Ukraine, Japan, Argentina, Brazil, Canada, Poland
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants

Renal Impairment

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) (ICONIC-TOTAL)

Plaque Psoriasis

United States, Korea, Republic of, Hungary, United Kingdom, Canada, Germany, Poland, Turkey, Taiwan, Spain, Argentina
Janssen Research & Development, LLC

Terminated

A Study of JNJ-69095897 in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of JNJ-68179280 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]-JNJ-70099731 in Healthy Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease

Alzheimer Disease

Belgium, Spain, Netherlands, Germany
Janssen Research & Development, LLC

Terminated

A Study of JNJ-53718678 in Participants With Hepatic Impairment

Hepatic Impairment

United States
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study of JNJ-64140284 in Healthy Male Participants (AMPAR)

Healthy

Belgium
Janssen Pharmaceutical K.K.

Withdrawn

A Study of JNJ-75105186 in Healthy Japanese and Chinese Participants

Healthy

Japan
Janssen Research & Development, LLC

No longer available

Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection

H7N9 Subtype of Influenza A Virus
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

Healthy

United States
Janssen-Cilag International NV

Completed

Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy Participants

Healthy

Netherlands
Janssen Sciences Ireland UC

Completed

A Study of JNJ-73763989 in Healthy Japanese Adult Participants

Healthy

United Kingdom
Janssen Pharmaceutical K.K.

Terminated

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants

Healthy

Japan
Janssen Research & Development, LLC

Completed

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55375515 in Healthy Participants

Healthy

Belgium

3

Subscribe